Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
Trinity team’s gene therapy offers promising glaucoma and AMD treatment
Research by investigators at Trinity College in Dublin, Ireland shows how the gene therapy conferred significant protection for retinal ganglion cells
US FDA issues approval for Sandoz aflibercept-abzv (Enzeevu)
The biosimilar is indicated to improve and maintain visual acuity for patients with neovascular age-related macular degeneration
VEGF-C and VEGF-D signaling pathways: Potential targets for treating wet AMD
A novel formulation may prevent blood vessel growth and vascular leakage in the retina
Altos Biologics submits EMA Marketing Authorisation Application for aflibercept biosimilar ALT-L9
Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea
US FDA approves biosimilar aflibercept-mrbb (Ahzantive)
The drug is a biosimilar for aflibercept 2 mg (Eylea)
Espansione Group receives CE Mark approval for eye-light® photobiomodulation device
The flagship, light-based technology has received approval for applications in the anterior and posterior segments